The global transactions based valuation of US$3Bn is fair where we stand today. If we get FDA approval for Cu64 diagnostic, ignoring all other trials, if we are able to license/ partner with a BP, then the sales of just diagnostic in one condition can generate $100’s Mn in revenue per year IMO given current radio pharma constraints globally. What we want is a bidding war for this asset.
Have we not included the Cu67 CR seen recently? If we correctly value the Cu64-67 pair for the theranostic value then we cannot value it less than US $5Bn today.
AIMO.
Research/Valuation, page-542
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.23 |
Change
0.360(5.24%) |
Mkt cap ! $2.282B | |||
| Open | High | Low | Value | Volume |
| $7.05 | $7.27 | $6.86 | $9.068M | 1.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2748 | $7.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.24 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |